Blog
RSS FeedPosted by Michael Wonder on 17 May 2023
Risankizumab for previously treated moderately to severely active Crohn's disease
17 May 2023 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for patients 16 years of ...
Posted by Michael Wonder on 14 May 2023
Negotiations begin for a new medicine pricing scheme
4 May 2023 - Negotiations for a new voluntary scheme for branded medicines pricing to open between the government, NHS ...
Posted by Michael Wonder on 10 May 2023
Olaparib for previously treated BRCA mutation positive hormone-relapsed metastatic prostate cancer
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate ...
Posted by Michael Wonder on 10 May 2023
Olaparib for adjuvant treatment of BRCA mutation positive HER2 negative high-risk early breast cancer after chemotherapy
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation positive HER2 ...
Posted by Michael Wonder on 09 May 2023
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies
9 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using belantamab ...
Posted by Michael Wonder on 04 May 2023
Access to cancer medicines in the UK
1 May 2023 - On 31 January 2020, the UK formally ended it's 47 year membership of the EU. As a ...
Posted by Michael Wonder on 04 May 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping
3 May 2023 - NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with ...
Posted by Michael Wonder on 03 May 2023
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
3 May 2023 - NICE has issued evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, ...
Posted by Michael Wonder on 03 May 2023
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
3 May 2023 - NICE has issued evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large ...
Posted by Michael Wonder on 03 May 2023
Voclosporin with mycophenolate mofetil for treating lupus nephritis
3 May 2023 - NICE has issued evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in ...
Posted by Michael Wonder on 03 May 2023
Ripretinib for treating advanced gastro-intestinal stromal tumour after three or more treatments
3 May 2023 - NICE has issued evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after ...
Posted by Michael Wonder on 29 Apr 2023
Prioritising patients in negotiations over drug pricing
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
Posted by Michael Wonder on 24 Apr 2023
NICE collaborates with international partner agencies to streamline the confidential marking process
24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...
Posted by Michael Wonder on 20 Apr 2023
Tezepelumab for the treatment of patients with severe asthma
20 April 2023 - NICE has published evidence based recommendations on tezepelumab (Tezspire) for the treatment of patients 12 years ...
Posted by Michael Wonder on 17 Apr 2023
Daratumumab in combination with bortezomib and dexamethasone for the treatment of patients with previously treated multiple myeloma
17 April 2023 - NICE has published final draft guidance on the use of daratumumab in combination with bortezomib and ...